ZYVERSA THERAPEUTICS INC (ZVSA) Fundamental Analysis & Valuation

NASDAQ:ZVSA • US98987D3008

Current stock price

0.3113 USD
-0.24 (-43.3%)
At close:
0.289 USD
-0.02 (-7.16%)
After Hours:

This ZVSA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ZVSA Profitability Analysis

1.1 Basic Checks

  • ZVSA had negative earnings in the past year.
  • ZVSA had a negative operating cash flow in the past year.
  • In the past 5 years ZVSA always reported negative net income.
  • ZVSA had a negative operating cash flow in each of the past 5 years.
ZVSA Yearly Net Income VS EBIT VS OCF VS FCFZVSA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • ZVSA has a Return On Assets of -42.14%. This is comparable to the rest of the industry: ZVSA outperforms 55.04% of its industry peers.
  • ZVSA's Return On Equity of -108.77% is in line compared to the rest of the industry. ZVSA outperforms 43.70% of its industry peers.
Industry RankSector Rank
ROA -42.14%
ROE -108.77%
ROIC N/A
ROA(3y)-182.17%
ROA(5y)-622.67%
ROE(3y)-364.67%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZVSA Yearly ROA, ROE, ROICZVSA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

  • ZVSA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZVSA Yearly Profit, Operating, Gross MarginsZVSA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. ZVSA Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for ZVSA has been increased compared to 1 year ago.
  • ZVSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ZVSA Yearly Shares OutstandingZVSA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
ZVSA Yearly Total Debt VS Total AssetsZVSA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -9.49, we must say that ZVSA is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -9.49, ZVSA is doing worse than 72.12% of the companies in the same industry.
  • There is no outstanding debt for ZVSA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.49
ROIC/WACCN/A
WACCN/A
ZVSA Yearly LT Debt VS Equity VS FCFZVSA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 20M 40M 60M 80M

2.3 Liquidity

  • ZVSA has a Current Ratio of 0.18. This is a bad value and indicates that ZVSA is not financially healthy enough and could expect problems in meeting its short term obligations.
  • ZVSA has a worse Current ratio (0.18) than 95.86% of its industry peers.
  • ZVSA has a Quick Ratio of 0.18. This is a bad value and indicates that ZVSA is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of ZVSA (0.18) is worse than 95.68% of its industry peers.
Industry RankSector Rank
Current Ratio 0.18
Quick Ratio 0.18
ZVSA Yearly Current Assets VS Current LiabilitesZVSA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. ZVSA Growth Analysis

3.1 Past

  • ZVSA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 99.60%, which is quite impressive.
EPS 1Y (TTM)99.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.96%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ZVSA will show a very negative growth in Earnings Per Share. The EPS will decrease by -21.81% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y93%
EPS Next 2Y33.34%
EPS Next 3Y-38.29%
EPS Next 5Y-21.81%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZVSA Yearly Revenue VS EstimatesZVSA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 20M 40M 60M 80M
ZVSA Yearly EPS VS EstimatesZVSA Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 -200 -400 -600

More info and screens

Find the best growth stocksShow best growing peers

0

4. ZVSA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ZVSA. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZVSA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZVSA Price Earnings VS Forward Price EarningsZVSA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZVSA Per share dataZVSA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

  • A cheap valuation may be justified as ZVSA's earnings are expected to decrease with -38.29% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.34%
EPS Next 3Y-38.29%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ZVSA Dividend Analysis

5.1 Amount

  • ZVSA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ZVSA Fundamentals: All Metrics, Ratios and Statistics

ZYVERSA THERAPEUTICS INC

NASDAQ:ZVSA (7/16/2025, 8:00:02 PM)

After market: 0.289 -0.02 (-7.16%)

0.3113

-0.24 (-43.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12
Earnings (Next)08-07
Inst Owners7.44%
Inst Owner Change0%
Ins Owners0.04%
Ins Owner Change0%
Market Cap1.52M
Revenue(TTM)N/A
Net Income(TTM)-8.84M
Analysts82.5
Price Target122.4 (39218.98%)
Short Float %3.67%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.19
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-7.18
EYN/A
EPS(NY)-3.98
Fwd EYN/A
FCF(TTM)-1.14
FCFYN/A
OCF(TTM)-1.14
OCFYN/A
SpS0
BVpS1.67
TBVpS-2.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.14%
ROE -108.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-182.17%
ROA(5y)-622.67%
ROE(3y)-364.67%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.18
Quick Ratio 0.18
Altman-Z -9.49
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.96%
EPS Next Y93%
EPS Next 2Y33.34%
EPS Next 3Y-38.29%
EPS Next 5Y-21.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y33.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y38.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.98%
OCF growth 3YN/A
OCF growth 5YN/A

ZYVERSA THERAPEUTICS INC / ZVSA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ZYVERSA THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 1 / 10 to ZVSA.


Can you provide the valuation status for ZYVERSA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to ZYVERSA THERAPEUTICS INC (ZVSA). This can be considered as Overvalued.


Can you provide the profitability details for ZYVERSA THERAPEUTICS INC?

ZYVERSA THERAPEUTICS INC (ZVSA) has a profitability rating of 1 / 10.


What is the expected EPS growth for ZYVERSA THERAPEUTICS INC (ZVSA) stock?

The Earnings per Share (EPS) of ZYVERSA THERAPEUTICS INC (ZVSA) is expected to grow by 93% in the next year.